NCT07338669 Hamburg Acute Kidney Injury Study (HAKIS)
| NCT ID | NCT07338669 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf |
| Condition | Acute Kidney Injury |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-09-16 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-09-16 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Hamburg Acute Kidney Injury Study (HAKIS) is a prospective observational cohort study aimed at investigating the mechanisms, risk factors, and clinical determinants of acute kidney injury (AKI) trajectories and consequences.
Eligibility Criteria
Inclusion Criteria: * Hospitalized individuals with acute kidney injury (AKI), defined by the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria or hospitalized individuals with acute illness who have not developed AKI (control group) * Age ≥ 18 years at time of enrollment * Written informed consent provided by the participant or, in participants lacking decision-making capacity, by a legal representative or healthcare proxy, where available. Participants lacking decision-making capacity without an available legal representative or healthcare proxy may be enrolled if participation is not contrary to their presumed wishes, in accordance with the ethics committee-approved consent procedure. Written informed consent is subsequently sought from the participant upon regaining decision-making capacity or from a legal representative, as applicable. Exclusion Criteria: * None
Contact & Investigator
Tobias B Huber, MD
PRINCIPAL INVESTIGATOR
Universitätsklinikum Hamburg-Eppendorf
Frequently Asked Questions
Who can join the NCT07338669 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07338669 currently recruiting?
Yes, NCT07338669 is actively recruiting participants. Contact the research team at c.schmidt-lauber@uke.de for enrollment information.
Where is the NCT07338669 trial being conducted?
This trial is being conducted at Hamburg, Germany.
Who is sponsoring the NCT07338669 clinical trial?
NCT07338669 is sponsored by Universitätsklinikum Hamburg-Eppendorf. The principal investigator is Tobias B Huber, MD at Universitätsklinikum Hamburg-Eppendorf. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.